 OTTAWA, Dec. 23, 2020 GLOBE NEWSWIRE -- OraSure Technologies, Inc. NASDAQ: OSUR, a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgeneORAL OMOME-505 collection device was included in the U.S. Food and Drug Administration FDA Emergency Use Authorization EUA amendment granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India. This is the seventh customer EUA that includes a collection device from the companys DNA Genotek subsidiary. 